Back to results
US 9,957,490 B1Granted
Cells comprising engineered nucleic-acid targeting nucleic acids
AssigneeCaribou Biosciences, Inc.
InventorsPaul Daniel Donohoue, Andrew Paul May
Life of this patent
Estimating the term…
Abstract
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof. Nucleic acid sequences encoding the engineered cross-type-nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Claims20
A cell comprising:
- an engineered CRISPR Class 2 cross-type-nucleic-acid targeting nucleic acid (“CRISPR Class 2 cross-type-NATNA”) comprising,
- a CRISPR Type V Cpf1-associated nucleic-acid targeting nucleic acid, having a 5′ end and a 3′ end, comprising a spacer element complementary to a first nucleic acid target sequence (“Cpf1-NATNA”),
- a first CRISPR Type II Cas9-associated nucleic-acid targeting nucleic acid, having a 5′ end and a 3′ end, comprising a spacer element complementary to a second nucleic acid target sequence (“first Cas9-NATNA”), and
- a second CRISPR Type II Cas9-associated nucleic-acid targeting nucleic acid, having a 5′ end and a 3′ end, comprising a tracr element (“second Cas9-NATNA”),
- wherein the first Cas9-NATNA or the second Cas9-NATNA is connected with the Cpf1-NATNA.
2 more elements
Dependencies are inferred from the claim text.